

LIFECARE ASA: MANDATORY NOTIFICATION OF TRADE

Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") on 2 March 2026 regarding the commencement of the exercise period for Warrants Series 1 issued in connection with the partially underwritten rights issue completed in January 2026. Each Warrant Series 1 entitles the holder to subscribe for one new share in the Company at an exercise price of NOK 0.3342 per share.

The exercise period for Warrants Series 1 commenced on 2 March 2026 and expires at 16:30 (CET) on 13 March 2026 (the "Exercise Period").

Warrants Series 1 are listed and tradable on Euronext Oslo Børs under the ticker code "LIFEJ". Trading in Warrants Series 1 will be halted five trading days prior to the expiry of the Exercise Period in order to facilitate settlement of exercised warrants. Consequently, Warrants Series 1 will be tradable up to and including today 6 March 2026 at 16:30 (CET).

Warrants Series 1 not sold on or before today at 16:30 (CET) or not exercised on or before 13 March 2026 at 16:30 (CET) will lapse without compensation. Holders of Warrants Series 1 who do not exercise their warrants may experience dilution of their shareholding in the Company.

The Company has been informed that Morten Foros Krohnstad, Chair of the Board and primary insider of the Company, has purchased 600,000 Warrants Series 1 at a price of NOK 0.004 per warrant.

Following this transaction, Morten Foros Krohnstad holds 0 shares and 1,600,000 Warrants Series 1 in the Company.

Please see the attached notification form for further details.

This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.



PRESS RELEASE
06 March 2026 14:14:00 CET

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-06 14:14 CET.

Attachments

[260306 PDMR Attachment – Morten Foros Krohnstad](#)